Up­dat­ed: Study shows As­traZeneca's Covid-19 mAb Evusheld may not work against dom­i­nant Omi­cron strain

As­traZeneca’s pro­phy­lac­tic treat­ment for Covid-19, known as Evusheld, has sur­vived where oth­er mAbs failed, show­ing ef­fi­ca­cy for the im­muno­com­pro­mised and oth­ers who can­not be vac­ci­nat­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER